MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
MoonLake Immunotherapeutics
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$9.75+0.20 (+2.09%)
Close on Oct 19, 2026
- Market cap
- $720.67M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.63 (+6.91%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $720.67M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.68
- Dividend yield
- –
- Free cash flow yield
- -31.25%
Fundamentals
- Net income
- -$263.67M
- EPS, diluted
- -$3.84
- Free cash flow
- -$225.18M
- Book value per share
- $5.79
- Diluted shares
- 74M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Operating income
-$268.34M
Net income
-$263.67M
EPS, diluted
-$3.84
Free cash flow
-$225.18M
Reported periodTrailing twelve months